Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of CAR-T Therapy in Haematological Malignancy will have significant change from previous year. By the most conservative estimates of global CAR-T Therapy in Haematological Malignancy market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the CAR-T Therapy in Haematological Malignancy market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy in Haematological Malignancy market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the CAR-T Therapy in Haematological Malignancy, covering the supply chain analysis, impact assessment to the CAR-T Therapy in Haematological Malignancy market size growth rate in several scenarios, and the measures to be undertaken by CAR-T Therapy in Haematological Malignancy companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
Allogeneic
Autologous
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Hospitals
Cancer Research Centers
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Celgene (Juno Therapeutics)
Bluebird Bio
Novartis
Pfizer
CARsgen Therapeutics
Gilead (Kite Pharma)
Sorrento Therapeutics
Autolus Therapeutics
Mustang Bio
Aurora BioPharma
Collectis
Celyad
Allogene Therapeutics
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global CAR-T Therapy in Haematological Malignancy market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of CAR-T Therapy in Haematological Malignancy market by identifying its various subsegments.
Focuses on the key global CAR-T Therapy in Haematological Malignancy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the CAR-T Therapy in Haematological Malignancy with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of CAR-T Therapy in Haematological Malignancy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
1.7 What is the Impact of Covid-19 Outbreak On the CAR-T Therapy in Haematological Malignancy?
1.7.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.7.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.7.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global CAR-T Therapy in Haematological Malignancy Market Size in 2020, by Scenario
1.7.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2015-2025
2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region
2.2 CAR-T Therapy in Haematological Malignancy Segment by Type
2.2.1 Allogeneic
2.2.2 Allogeneic
2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type
2.3.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (2015-2020)
2.4 CAR-T Therapy in Haematological Malignancy Segment by Application
2.4.1 Hospitals
2.4.2 Cancer Research Centers
2.4.3 Others
2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application
2.5.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Application (2015-2020)
3 Global CAR-T Therapy in Haematological Malignancy by Players
3.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players
3.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Players (2018-2020)
3.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players (2018-2020)
3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CAR-T Therapy in Haematological Malignancy by Regions
4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions
4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth
4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth
4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth
4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth
5 Americas
5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Countries
5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type
5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Regions
6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type
6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe CAR-T Therapy in Haematological Malignancy by Countries
7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Countries
8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type
8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global CAR-T Therapy in Haematological Malignancy Market Forecast
10.1 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast (2021-2025)
10.2 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions
10.2.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2021-2025)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Type
10.8 Global CAR-T Therapy in Haematological Malignancy Forecast by Application
11 Key Players Analysis
11.1 Celgene (Juno Therapeutics)
11.1.1 Company Details
11.1.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.1.4 Main Business Overview
11.1.5 Celgene (Juno Therapeutics) News
11.2 Bluebird Bio
11.2.1 Company Details
11.2.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.2.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.2.4 Main Business Overview
11.2.5 Bluebird Bio News
11.3 Novartis
11.3.1 Company Details
11.3.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.3.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.3.4 Main Business Overview
11.3.5 Novartis News
11.4 Pfizer
11.4.1 Company Details
11.4.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.4.4 Main Business Overview
11.4.5 Pfizer News
11.5 CARsgen Therapeutics
11.5.1 Company Details
11.5.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.5.4 Main Business Overview
11.5.5 CARsgen Therapeutics News
11.6 Gilead (Kite Pharma)
11.6.1 Company Details
11.6.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.6.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.6.4 Main Business Overview
11.6.5 Gilead (Kite Pharma) News
11.7 Sorrento Therapeutics
11.7.1 Company Details
11.7.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.7.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.7.4 Main Business Overview
11.7.5 Sorrento Therapeutics News
11.8 Autolus Therapeutics
11.8.1 Company Details
11.8.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.8.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.8.4 Main Business Overview
11.8.5 Autolus Therapeutics News
11.9 Mustang Bio
11.9.1 Company Details
11.9.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.9.4 Main Business Overview
11.9.5 Mustang Bio News
11.10 Aurora BioPharma
11.10.1 Company Details
11.10.2 CAR-T Therapy in Haematological Malignancy Product Offered
11.10.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)
11.10.4 Main Business Overview
11.10.5 Aurora BioPharma News
11.11 Collectis
11.12 Celyad
11.13 Allogene Therapeutics
12 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global CAR-T Therapy in Haematological Malignancy Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by CAR-T Therapy in Haematological Malignancy Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Allogeneic
Table 7. Major Players of Autologous
Table 8. CAR-T Therapy in Haematological Malignancy Market Size by Type (2014-2019) ($ Millions)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Table 10. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)
Table 11. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
Table 12. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2020) ($ Millions)
Table 13. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2020)
Table 14. Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
Table 15. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2015-2020 ($ Millions)
Table 19. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions 2015-2020
Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)
Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)
Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)
Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Table 24. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)
Table 25. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020) ($ Millions)
Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2015-2020)
Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)
Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Table 30. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)
Table 31. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)
Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)
Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)
Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)
Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)
Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)
Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)
Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Table 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)
Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)
Table 44. Key and Potential Regions of CAR-T Therapy in Haematological Malignancy
Table 45. Key Application and Potential Industries of CAR-T Therapy in Haematological Malignancy
Table 46. Key Challenges of CAR-T Therapy in Haematological Malignancy
Table 47. Key Trends of CAR-T Therapy in Haematological Malignancy
Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2021-2025) ($ Millions)
Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions
Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2021-2025) ($ Millions)
Table 51. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2021-2025)
Table 52. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2021-2025) ($ Millions)
Table 53. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2021-2025)
Table 54. Celgene (Juno Therapeutics) Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 55. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
Table 56. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 57. Celgene (Juno Therapeutics) Main Business
Table 58. Celgene (Juno Therapeutics) Latest Developments
Table 59. Bluebird Bio Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 60. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 61. Bluebird Bio Main Business
Table 62. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 63. Bluebird Bio Latest Developments
Table 64. Novartis Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 65. Novartis CAR-T Therapy in Haematological Malignancy Product Offered
Table 66. Novartis Main Business
Table 67. Novartis CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 68. Novartis Latest Developments
Table 69. Pfizer Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 70. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
Table 71. Pfizer Main Business
Table 72. Pfizer CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 73. Pfizer Latest Developments
Table 74. CARsgen Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 75. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 76. CARsgen Therapeutics Main Business
Table 77. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 78. CARsgen Therapeutics Latest Developments
Table 79. Gilead (Kite Pharma) Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 80. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
Table 81. Gilead (Kite Pharma) Main Business
Table 82. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 83. Gilead (Kite Pharma) Latest Developments
Table 84. Sorrento Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 85. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 86. Sorrento Therapeutics Main Business
Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 88. Sorrento Therapeutics Latest Developments
Table 89. Autolus Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 90. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 91. Autolus Therapeutics Main Business
Table 92. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 93. Autolus Therapeutics Latest Developments
Table 94. Mustang Bio Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 95. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 96. Mustang Bio Main Business
Table 97. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 98. Mustang Bio Latest Developments
Table 99. Aurora BioPharma Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 100. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
Table 101. Aurora BioPharma Main Business
Table 102. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)
Table 103. Aurora BioPharma Latest Developments
Table 104. Collectis Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 105. Celyad Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
Table 106. Allogene Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors
List of Figures
Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 2. Market Research Methodology
Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2015-2025 ($ Millions)
Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)
Figure 5. Global Allogeneic Market Size Growth Rate
Figure 6. Global Autologous Market Size Growth Rate
Figure 7. CAR-T Therapy in Haematological Malignancy in Hospitals
Figure 8. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2015-2020) ($ Millions)
Figure 9. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers
Figure 10. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2015-2020) ($ Millions)
Figure 11. CAR-T Therapy in Haematological Malignancy in Others
Figure 12. Global CAR-T Therapy in Haematological Malignancy Market: Others (2015-2020) ($ Millions)
Figure 13. Global Others YoY Growth ($ Millions)
Figure 14. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019
Figure 15. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions 2015-2020
Figure 16. Americas CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)
Figure 17. APAC CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)
Figure 18. Europe CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)
Figure 19. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)
Figure 20. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019
Figure 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019
Figure 22. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019
Figure 23. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 24. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 25. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 26. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions in 2019
Figure 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019
Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019
Figure 29. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 30. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 31. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 32. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 33. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 34. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019
Figure 36. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019
Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019
Figure 38. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 39. France CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 40. UK CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 41. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 42. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 43. Spain CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 44. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019
Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019
Figure 46. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019
Figure 47. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 48. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 49. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 50. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 51. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)
Figure 52. Global CAR-T Therapy in Haematological Malignancy arket Size Forecast (2021-2025) ($ Millions)
Figure 53. Americas CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 54. APAC CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 55. Europe CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 57. United States CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 58. Canada CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 59. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 61. China CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 62. Japan CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 63. Korea CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 65. India CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 66. Australia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 67. Germany CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 68. France CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 69. UK CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 70. Italy CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 71. Russia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 72. Spain CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 73. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 74. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 75. Israel CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 76. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Figure 77. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets